These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9623094)

  • 1. [Taxoids in ovarian and breast carcinoma: the role of the medical profession and the government].
    Slee PH; Eliel MR; Nortier JW; Rodenburg CJ
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):502-4. PubMed ID: 9623094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Provision of taxoids in 1996: inequality of care].
    Eland IA; Otter R; Krommendijk R; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):518-21. PubMed ID: 9623098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and docetaxel. Innovation, but at what cost?
    Lønning PE
    Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
    [No Abstract]   [Full Text] [Related]  

  • 4. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
    Brown RE; Hutton J
    Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE; Hutton J; Burrell A
    Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical rationale for developing docetaxel (Taxotere).
    Armand JP
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Taxanes in the treatment of breast and ovarian cancers: current indications and results].
    Espié M; Cuvier C; Gorins A; Marty M
    Contracept Fertil Sex; 1998 Nov; 26(11):805-11. PubMed ID: 9864888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer treatments rationed by authority.
    Halle M
    BMJ; 1996 Sep; 313(7060):774. PubMed ID: 8842067
    [No Abstract]   [Full Text] [Related]  

  • 12. Docetaxel.
    Leahy M; Howell A
    Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
    D'Andrea GM; Seidman AD
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility in second-line metastatic breast cancer.
    Berdeaux G; Hurteloup P
    Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
    Partridge A; Winer E
    Clin Breast Cancer; 2000 Jul; 1(2):164-5. PubMed ID: 11899655
    [No Abstract]   [Full Text] [Related]  

  • 16. The taxanes: an update.
    Crown J; O'Leary M
    Lancet; 2000 Apr; 355(9210):1176-8. PubMed ID: 10791395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (Taxotere) for advanced breast cancer.
    Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
    [No Abstract]   [Full Text] [Related]  

  • 19. An expanding role for docetaxel.
    Hortobagyi G
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):1-3. PubMed ID: 9865684
    [No Abstract]   [Full Text] [Related]  

  • 20. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.